Dr Chin is currently the CEO of Institute for OneWorld Health, a nonprofit pharmaceutical company. Dr Chin joined OneWorld Health from OXiGENE, a developer of vascular targeting drugs for oncology and ophthalmology, where he served as president and CEO.
Previously, Dr Chin served as senior vice president and head of global development for Elan. Dr Chin currently serves on the board of directors of Genmedica located in Barcelona, Spain.
Sanford Hillsberg, chairman of board of directors of RXi Pharmaceuticals, said: “Dr Chin has a wide range of experience in the drug development industry and will provide a wealth of knowledge and insight as RXi moves into developing its RNAi therapies. Dr Chin will provide experienced support and advice as RXi moves into the next stage of its drug development.”